Stocks and Investing Stocks and Investing
Tue, January 3, 2023

Derek Archila Upgraded (BPMC) to Hold and Held Target at $41 on, Jan 3rd, 2023


Published on 2024-10-28 00:42:57 - WOPRAI, Derek Archila
  Print publication without navigation


Derek Archila of Wells Fargo, Upgraded "Blueprint Medicines Corporation" (BPMC) to Hold and Held Target at $41 on, Jan 3rd, 2023.

Derek has made no other calls on BPMC in the last 4 months.



There are 11 other peers that have a rating on BPMC. Out of the 11 peers that are also analyzing BPMC, 4 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $53 on, Monday, December 12th, 2022
  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $52 on, Wednesday, November 2nd, 2022
  • Matthew Biegler of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, November 2nd, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $75 on, Wednesday, November 2nd, 2022


These are the ratings of the 7 analyists that currently disagree with Derek


  • Ami Fadia of "Needham" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
  • Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $114 on, Friday, November 4th, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $108 on, Thursday, November 3rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $70 on, Wednesday, November 2nd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $106 on, Wednesday, November 2nd, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, November 2nd, 2022
  • Zhiqiang Shu of "Berenberg" Initiated at Strong Buy and Held Target at $90 on, Wednesday, September 14th, 2022
Contributing Sources